While results so far may seem to support a link between increased access to cannabis and a reduction in prescription opioid use, findings from a study published in 2018 found otherwise.
Package inserts of opioid analgesics may not consistently provide information regarding safe drug storage and/or disposal.
A longer duration of extended-release naltrexone treatment in individuals with opioid dependence was associated with improved outcomes and reduced rates of relapse.
Because even moderate reductions in adolescent drinking and alcohol use disorders have the potential to reduce short- and long-term public health harms, these findings support broad implementation of the program.
The investigators found that antisocial (β=0.23) and borderline (β=0.20) personality disorders were strongly associated with cannabis use as well as with cannabis use disorder.
The findings of these analyses suggest that, to an extent, this relationship might be generalized to cannabis users as a whole, not just those diagnosed with a cannabis use disorder.
The more chemicals in e-liquid, the more toxic it is likely to be.
Online marijuana searches grew by 98 percent as a proportion of all searches from 2005 to 2017.
If approved, Lucemyra will be the first non-opioid medication indicated to mitigate opioid withdrawal symptoms.
E-cigarettes are associated with more harm than good on a population level.
Most adolescent users of tobacco products do not identify as users.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- #MeToo: Helping Victims Cope With Sexual Harassment
- Clinician Insight: Exploring the Link Between Bipolar Disorder and Binge Eating Disorder
- Association Between Psychosis and Development of Dementia in Older Men
- Psychosis Could Be a Potential Side Effect of Steroid Treatment in Kids
- Effects of Antipsychotic Drugs on the Cardiovascular System
- Triiodothyronine in the Treatment of Bipolar Depression
- Nutritional Influences on Bipolar Disorder in Children
- Old Challenges and New Directions in Managing Tardive Dyskinesia
- Similar Rates of Childhood Trauma in Schizophrenia and Substance Use Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Psychiatric Comorbidities Increase Neurologic Disability in Multiple Sclerosis
- Self-Regulation Interventions Beneficial for Children
- Traumatic Brain Injury Associated With Increased Risk for Dementia
- Adverse Neurodevelopmental and Mental Health Outcomes in PCOS
- Depression and Sleep Disturbances: Common Bedfellows